Dupilumab Treatment in Children Aged 6–11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study

BACKGROUND: The management of paediatric atopic dermatitis (AD) is challenging, mostly relying on emollients and topical corticosteroids. Dupilumab, a fully human monoclonal antibody, has been recently approved for the treatment of children aged 6–11 years with moderate-to-severe AD not adequately c...

Descripción completa

Detalles Bibliográficos
Autores principales: Napolitano, Maddalena, Fabbrocini, Gabriella, Neri, Iria, Stingeni, Luca, Boccaletti, Valeria, Piccolo, Vincenzo, Amoruso, Giuseppe Fabrizio, Malara, Giovanna, De Pasquale, Rocco, Di Brizzi, Eugenia Veronica, Diluvio, Laura, Bianchi, Luca, Chiricozzi, Andrea, Di Guida, Adriana, Del Duca, Elisabetta, Moschese, Viviana, Di Lernia, Vito, Dragoni, Federica, Gruber, Michaela, Hansel, Katharina, Licari, Amelia, Manti, Sara, Leonardi, Salvatore, Mastorino, Luca, Ortoncelli, Michela, Provenzano, Eugenio, Palermo, Antonino, Patella, Vincenzo, Peduto, Tiziana, Pezzolo, Elena, Piras, Viviana, Potestio, Luca, Battista, Teresa, Satta, Rosanna, Termine, Stefania, Palma, Paolo, Zangari, Paola, Patruno, Cataldo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9417930/
https://www.ncbi.nlm.nih.gov/pubmed/36028611
http://dx.doi.org/10.1007/s40272-022-00531-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9417930/
https://www.ncbi.nlm.nih.gov/pubmed/36028611
http://dx.doi.org/10.1007/s40272-022-00531-0

Ejemplares similares